Peter Altman

Peter Altman

Algemeen Directeur bij BIOCARDIA, INC.

Vermogen: 279 526 $ op 31-05-2026

59 jaar
Health Technology
Consumer Services

Profiel

Peter Alan Altman was the founder of CareDx, Inc., founded in 1998, where the title held was Director from 2003 to 2014.
Dr. Altman was the founder of Lumen Therapeutics, founded in 2004, where the title held was Chief Executive Officer from 2004 to 2005.
Dr. Altman is also the founder of Sinus Rhythm Technologies, Inc...
Dr. Altman is currently President, Chief Executive Officer & Director at BioCardia, Inc. since 2002.
Dr. Altman is Chief Executive Officer at BioCardia Lifesciences, Inc. Dr. Altman is Director at Oncocyclist Biotech since 2018.
Former jobs include President, Chief Executive Officer & Director at BioCardia, Inc. and Principal at Ventritex, Inc. Education includes a doctorate from the University of California, Berkeley, a doctorate from The University of California, San Francisco, and undergraduate and graduate degrees from Fu Foundation School of Engineering & Applied Science.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
18-06-2026 300.566 ( 2,64% ) 279 526 $ 31-05-2026

Actieve functies van Peter Altman

BedrijvenFunctieBegin
BIOCARDIA, INC. Algemeen Directeur 01-01-2002
Oncocyclist Biotech
Directeur/Bestuurslid 01-01-2018
Algemeen Directeur -

Eerdere bekende functies van Peter Altman

BedrijvenFunctieEinde
CAREDX, INC. Oprichter 01-01-2014
Algemeen Directeur 01-01-2005
Algemeen Directeur -
Corporate Officer/Principal -
Corporate Officer/Principal -
Ervaring van Peter Altman in detail bekijken

Opleiding van Peter Altman

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

32

Eerstegraads connecties

11

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit11

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Oncocyclist Biotech

  1. Beurs
  2. Insiders
  3. Peter Altman